CDA Technology is a
Game Changer.
ANPAC BIO'S CDA (CANCER DIFFERENTIATION ANALYSIS) IS A REVOLUTIONARY TECHNOLOGY.
LEARN MORE
Results Speak.
20+

CANCER TYPES

~150

SCREENED OUT CASES

75%
TO
90%

ACCURACY RATE

100K+

CONFIRMED TESTS

About Anpac Bio

Decades of research by the world’s most respected cancer scientists and physicians consistently reveals one conclusion:

Most people can survive cancer if the disease is caught early.

This fact led Anpac Bio Co-Founders, Dr. Chris Yu and Dr. Herbert Yu, to ask the question that ultimately launched the company:

“What if we could detect cancer before tumors start?”

Achieving that goal became the Anpac Co-Founders’ quest. They began breaking the problem apart—drawing on expertise in:

  • Cancer research
  • Bio-chemistry
  • Chemistry
  • Nano-technology
  • Surface science
  • Material science
  • Detection
  • Physics
  • Engineering and manufacturing

Together they founded Anpac Bio-Medical Science Co., Ltd. in 2008, bringing together a multi-national team of medical, biomedical and nanotechnology scientists, and engineering experts. Their unique, cross-disciplinary approach combines numerous fields of science, medicine and engineering to achieve vastly superior early cancer screening and detection technology.

LEARN MORE

Meet the People Who Are Changing the Game
LEARN MORE